- European Drug Regulatory Agency found connection between AstraZeneca vaccine and blood clots
- Scientists claim – the benefits more than the disadvantages of this vaccine
- The agency is in favor of AstraZeneca’s vaccine, the bid-risk is very low
Today, the European Medical Agency (EMA) has said a big deal amidst doubts about the Corona vaccine of AstraZeneca in European countries. The European drug regulator has reported that it has found a possible connection between AstraZeneca’s corona virus vaccine and the problem of rare blood clots. However, the report also stated that the benefits of this vaccine still outweigh the risks.
Contact found between blood clotting and vaccine
The European Medicines Agency, in a statement released on Wednesday, did not announce any new restrictions on the use of the vaccine for people 18 years and older. Earlier this week, a senior agency official said a causal connection was found between AstraZeneca vaccines and rare blood clots in dozens of thousands of people worldwide.
Vaccine review is still going on
Marco Cavalleri, head of the Amsterdam-based agency’s Health Risk and Vaccine Strategy, told a Rome newspaper on Tuesday that it is becoming very difficult to tell if there is any causal relationship between AstraZeneca’s vaccines and the extremely rare clots of blood associated with platelet depletion. No contact. The agency stated that its evaluation has not yet reached a conclusion and is currently under review.
30 cases reported in Britain
The UK drug regulator had reported a few days ago that 30 cases of blood clotting had been identified with AstraZeneca’s Corona virus vaccine. However, even then the agency insisted that the benefits of this vaccine were more than any threat. The Drug and Health Care Regulatory Agency said that the risk associated with blood clotting in this way is very low and people should continue getting the vaccine.
Doubts about AstraZeneca’s vaccine in European countries
In Europe, some people who were vaccinated against the Oxford / AstraZeneca had reported cases of blood clots, after which concerns were expressed. Some countries, such as Germany, had asked people of certain age groups not to get this vaccine administered. At the same time, both the European Drug Monitoring Organization and the World Health Organization have said that the vaccine is safe and effective.